Background: Everolimus-eluting ABSORB Bioresorbable vascular scaffolds consisted of poly-lactide are programmed to bioresorb approximately in three years. It is still unknown how the struts implanted in front of a side branch behave during bioresorption. The purpose of this study was to assess the fate of bioresorbable struts jailing side branch ostia at 6, 24 months (cohort B1) or at 12 and 36 months after implantation of the BVS (cohort B2), with three-dimensional (3-D) optical coherence tomography (OCT) reconstruction. Methods: The ABSORB Cohort B trial is a multicentre single-arm trial to assess the safety and performance of the BVS. Fourier domain-OCT pullbacks were obtained at a pullback speed of 20 mm/s and 3-D rendering are computed. The area and the number of strut-free compartments at side branch ostium delineated by the BVS struts were evaluated. The endo-and abluminal coverages of the struts present at the ostium of sidebranch were quantified at 6, 12, 24 and 36 month follow-up.
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Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain, 2 Hospital Universitario Reina Sofia, University of Cordoba, Cordoba, Spain Background: In vitro and in vivo geometry of metallic single stent implantation in coronary bifurcated lesions after kissing balloon (KB) intervention, has been well studied. The same analysis of bioabsorbable vascular scaffolding (BVS) had not yet been reported. Our own in vitro observations with BVS showed integrity and no device fracture after KB inflation when a 2.5 mm balloon diameter was inflated through the struts. Methods: In our series, 80 coronary bifurcated lesions were treated with provisional BVS strategy. In 21 out of 80 lesions, we performed final KB inflation after BVS implantation. The reason for side branch (SB) intervention was ostial angiographic stenosis (present before BVS implantation in 14 lesions, and appearing after it in 7). IVUS studies were performed in 3 conditions: before treatment, immediately after BVS and after KB inflation. Measurements were performed at the proximal scaffold segment, before SB origin, under SB origin and at the distal segment. This study analyzes the ultrasonographic (IVUS) findings after BVS implantation and after KB inflation. For KB technique, the balloon diameter inflated in the MV was always 0.5 mm minor than BVS diameter and the SB balloon diameter was 2 or 2.5 mm. Results: BVS diameter was 3.10 AE 0.39 mm and the mean inflation pressure was 15AE1 atm. The MV balloon diameter was 2.8AE0.3 mm (0.5 mm minor than BVS diameter in all cases). The SB balloon diameter was 2.3AE0.2 mm and the inflation pressure of both balloons was 7-8 atm. Integrity of the device was always observed after KB. Good aposition of the proximal BVS and angiographic improvement of the SB origin was always obtained. Geometry of the BVS may be modified after KB technique, but nor distorted. The table summarizes the findings.
Conclusions: Final KB inflation in bifurcated coronary lesions treated with BVS is feasible, without inducing fracture or important distortion of the scaffold.
TCT-36
One Background: The aim of this study was to evaluate clinical outcomes of diabetic versus non-diabetics patients when treated with the Absorb Bioresorbable Vascular Scaffold (BVS) at 1-year follow-up. Methods: This interim post-hoc analysis included 101 patients of the ABSORB Cohort B trial and the first consecutive 450 patients of the ABSORB EXTEND trial with at least 1-year follow-up. These 2 trials had similar inclusion and exclusion criteria; 136 diabetic patients were compared to 415 non-diabetic patients. Primary end point was assessed by a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, and target lesion revascularization.
Results: There were no significant differences in baseline patient demographics and lesion characteristics between diabetic and non-diabetic patients treated with the Absorb BVS, except for the prevalence of hypertension requiring medications (75.0% in diabetics vs. 61.4% in non-diabetics, p¼0.004). The cumulative incidence of MACE did not differ between diabetic and non-diabetic patients treated with the Absorb BVS at 1-year follow-up (3.7% vs. 5.1%, p¼0.64). One patient out of 136 diabetic patients experienced definite late scaffold thrombosis (ST), whereas four ST events (1 definite and 1 probable subacute ST, and 1 definite and 1 possible late ST) were observed in the 415 non-diabetic patients. The incidence rate of definite/ probable ST was thus 0.7% in diabetic group and 0.7% in non-diabetic group (p¼1.0). Methods: 126 patients with single, de novo coronary artery lesions were enrolled in this prospective, multi-centre, single-arm study. Those patients receiving the study device are being analysed for multiple clinical endpoints including: Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, or clinically-indicated target lesion revascularization (CI-TLR); Clinically-indicated Target Lesion and Target Vessel Revascularization, (CI-TVR) and Stent Thrombosis assessed at 1, 6 and 12 months and annually to 5 years. All patients underwent angiographic assessment at 6 months and a subset of patients underwent IVUS and OCT assessment at 6 months and MSCT at 12 months. Results: At baseline, the patient population had a mean age 62 years, 32% were females, 21% were diabetic. Pre-procedure mean lesion length was 11.2 mm, RVD was 3.06 mm. Serial QCA imaging at 6 months demonstrated low mean in-scaffold late lumen loss (0.21mm.IVUS and OCT imaging indicated early vessel restoration at 6 months. Clinical events remained low (MACE ¼ 3.25% at 6 months) with no reports of definite stent thrombosis.
Conclusions:
The DESolve Nx NEBCSS demonstrated safety and efficacy in treating de novo coronary artery lesions with low clinical event rate and evidence of low late lumen loss at 6 months. A first report of results through 12 months will be presented.
TCT-38
Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis Scaffold (DREAMS) 3-year clinical data of cohort 1 and multi-modality imaging outcomes are reported. Methods: Forty-six subjects were enrolled in the first-in-man BIOSOLVE-I study in two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months; angiographic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12month. A subgroup of patients underwent OCT and vasomotion testing. The primary endpoint is Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12month for cohort 2. For some patients also 18-month and 24-month imaging data are available. Results: TLF rate at 24-month was 6.8% including 2 TLRs and 1 peri-procedural MI occurring at the 12-month follow-up angiography; no events emerged from 12-to 24-month. No cardiac death or scaffold thrombosis was observed. 36month clinical data of Cohort 1 will be available upon presentation. Vasoconstriction after acetylcholine at 6-month (Delta¼-10.04%; p¼0.0008 versus baseline) followed by vasodilatation after nitroglycerine (Delta¼8.69%; p<0.0001 versus baseline) demonstrates the uncaging aspect of the absorption process with no further change at the 12-month follow-up. Six-month virtual histology (VH) data showed a significant decrease in the dense calcium by 39.5% (p¼0.0015) remaining stable from 6-to 12-month follow-up. This decrease is interpreted as a surrogate assessment for the bioabsorption process of the scaffold material. Preliminary echogenicity data using the decrease in intensity of the ultrasound signal to quantify the change in strut structure demonstrate a relatively large decrease of hyperechogenicity (28.5%) in the first 6-month, followed by lower decrease (18.4%) in the 6 months thereafter, with indications that the hyperechogenicity at 18-month returns to the values seen preimplantation.
Conclusions: DREAMS shows excellent safety and efficacy data with no death and no scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality imaging documented the absorption process and the uncaging aspect of this device already at 6 months. Methods: The RESTORE trial is a prospective, multi-center and multi-national trial enrolling patients with single, de novo lesions in native coronary arteries with an average reference diameter between 2.9 mm to 3.3 mm and lesion length up to 12 mm. The primary study endpoint was freedom from ischemic-driven target lesion revascularization (TLR) at 6-months and 12-month in-scaffold late loss. Serial IVUS evaluation (post procedure and at 12 months) was also performed in a subgroup of patients. All imaging analyses were performed by independent core labs.
Results: A total of 26 patients were enrolled in this trial and the device was successfully implanted in 22 cases. Most patients were male (76%) and 36% of all patients had diabetes. Mean reference vessel diameter and lesion length were 2.72 mm and 11.1 mm, respectively. Acute recoil was minimal at 3.8% AE 6.7%. Through 6 months post-implant there were 2 focal in-scaffold TLRs. The 12-month QCA evaluation was completed for the first 8 patients and resulted in a late loss of 0.20 AE 0.19 mm. Of note, the mean stent diameter at implant in this initial group of patients was 2.94mm and remained constant over the 12-month follow-up period. The QCA and safety data for the remaining patients as well as full IVUS assessment will be available at the time of the meeting. Conclusions: In this preliminary assessment, the ReZolve scaffold showed excellent acute performance with minimal acute recoil. Complete 12-month QCA and IVUS data is required to confirm the performance of this novel device.
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